Navigation Links
CMPMedica Expands SearchMedica.com with Multiple Additional Vertical Search Applications co-developed with Convera(R)
Date:3/24/2008

clinical resources.

About CMPMedica

CMPMedica provides information and education to healthcare professionals and patients around the world. It has a unique portfolio of professional media products including newspapers, magazines, drug directories, electronic databases, websites and events.

About SearchMedica.com

SearchMedica.com indexes only authoritative medical information, approved for inclusion by medical editors and a physician editorial board. Medical professionals receive more relevant, smaller sets of search results from SearchMedica.com than from mainstream engines, which contain consumer- oriented, paid testimonials and other types of unreliable information. Since SearchMedica.com is advertiser supported, medical professionals pay nothing to use the specialty search engine. All SearchMedica search results are independent and unbiased. They contain well-known, credible journals, peer- reviewed research, and evidence-based articles written for practicing healthcare professionals. SearchMedica is currently available at http://www.SearchMedica.com.

About Convera(R)

Convera is the leading provider of search as a service for trade publishers and is the vertical search provider of choice for a growing number of specialist publishers around the world. Convera enables publishers to generate additional revenue by creating customized search applications for specialist audiences under their own brand and also manages the vertical search sites of a growing number of specialist publishers. Convera site search, vertical search and lead generation applications can combine publisher proprietary content with an editorially vetted best of the Web for specific professional audiences, providing an authoritative and comprehensive search experience. Many of the world's largest publishers are working with Convera to accelerate their e-publishing strategies, meet growing online reven
'/>"/>

SOURCE Convera
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Nova Biosource Fuels Expands Senior Executive Team
2. Finesse Solutions Expands by Opening Sales and Service Centers
3. Evotec Expands Collaboration With InterMune
4. Novo Nordisk Expands U.S. Headquarters in New Jersey
5. Tunnell Consulting Expands Biotechnology Expertise
6. Progen Expands Board of Directors
7. BioVascular, Inc. Expands Executive Team
8. United BioSource Expands Regulatory Affairs Capabilities
9. Valensa Expands Astaxanthin Extraction Capacity
10. Progen Expands Drug Development Pipeline Through Acquisition of CellGate
11. Touch Bionics expands U.S. presence to meet demand for i-LIMB Hand
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):New engineering institute to modify, develop technology for the global poor 2New engineering institute to modify, develop technology for the global poor 3Synthetic protein mimics structure, function of metalloprotein in nature 2Penn, Georgia collaboration awarded $14.6 million to expand pathogen database 2Penn, Georgia collaboration awarded $14.6 million to expand pathogen database 3Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 1Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 2Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 3Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 4Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 5Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 6Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 7Study Links Epilepsy to Brain Protein 57562 1Long time QHR Hospital Client Cary Medical Center Recognized with Top Leadership Team Award 57558 1Long time QHR Hospital Client Cary Medical Center Recognized with Top Leadership Team Award 57558 2Long time QHR Hospital Client Cary Medical Center Recognized with Top Leadership Team Award 57558 3Long time QHR Hospital Client Cary Medical Center Recognized with Top Leadership Team Award 57558 4